arrow_back Back to App

New Treatment Centers for Sickle Cell Disease and Related Conditions

This law establishes a program to fund treatment centers for sickle cell disease across the United States. These centers aim to provide patients with better access to coordinated medical care, support services, and education to improve their health and quality of life.
Key points
The law provides funding to create local treatment centers connecting hospitals/clinics with community organizations.
Centers will offer medical care, help with social needs, provide education, and assist with insurance and transportation.
The goal is to improve access to care, especially in areas with many sickle cell patients.
The Act supports collecting data to better understand and treat the disease.
Significant funding is authorized for these programs.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_4866
Sponsor: Sen. Van Hollen, Chris [D-MD]
Process start date: 2022-09-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Sickle Cell Disease Treatment Centers Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_4866.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-09-15.

What are the main provisions?

Key points include:

  • The law provides funding to create local treatment centers connecting hospitals/clinics with community organizations.
  • Centers will offer medical care, help with social needs, provide education, and assist with insurance and transportation.
  • The goal is to improve access to care, especially in areas with many sickle cell patients.
  • The Act supports collecting data to better understand and treat the disease.
  • Significant funding is authorized for these programs.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Van Hollen, Chris [D-MD].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health